Kiniksa Pharmaceuticals (KNSA)
(Delayed Data from NSDQ)
$25.44 USD
-0.28 (-1.09%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $25.44 0.00 (0.00%) 4:24 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$25.44 USD
-0.28 (-1.09%)
Updated Aug 14, 2024 04:00 PM ET
After-Market: $25.44 0.00 (0.00%) 4:24 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Zacks News
Gilead Teams Up With Kiniksa, Submits BLA for CAR T Therapy
by Zacks Equity Research
Gilead (GILD) collaborates with Kiniksa for a combination study and submits BLA for CAR T therapy candidate.
Company News For Nov 21, 2019
by Zacks Equity Research
Companies in the news are: URBN, KNSA, ACB, ENDP
Kiniksa Pharmaceuticals Enters Oversold Territory
by Zacks Equity Research
Kiniksa Pharmaceuticals, Ltd. (KNSA) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.
5 Best-Performing IPOs of 2018
by Nitish Marwah
Strong economic fundamentals and increased foreign investment have led to such a high number of companies going public.